SCHEDULE 13D/A: Hellman & Friedman Reduces Claritev Stake to 23.5%

Hellman & Friedman entities have reduced their beneficial ownership in Claritev Corporation to 23.5% through a secondary offering of 1.5 million shares at $51.50 per share.

Summary

• Hellman & Friedman entities, including H&F Corporate Investors VIII, Ltd. and Hellman & Friedman Investors VIII, L.P., now beneficially own an aggregate of 3,887,858 shares of Claritev Corporation's Class A Common Stock.
• This represents approximately 23.5% of the outstanding Class A Common Stock, based on 16,525,644 shares outstanding as of November 3, 2025.
• The Reporting Persons previously filed Schedule 13D on October 13, 2020, with amendments on November 16, 2020, and May 13, 2022.
• On November 12, 2025, several H&F Selling Stockholders entered into an underwriting agreement to sell 1,500,000 shares of Common Stock at a public offering price of $51.50 per share, less an underwriting discount of $2.8325 per share.
• The sale of these shares closed on November 14, 2025.
• Underwriters were granted an overallotment option to purchase up to an additional 225,000 shares. If exercised, the H&F entities' beneficial ownership would be approximately 22.2% (3,662,858 shares).
• The Issuer, its executive officers, directors, and the H&F Selling Stockholders are subject to a 60-day lock-up period from November 12, 2025, preventing further sales without underwriter consent.
• H&F Investors retain board nomination rights based on their ownership percentage relative to their original ownership on July 12, 2020. Currently, Allen Thorpe, an H&F executive, serves on the board.
• H&F Investors also hold customary registration rights, including unlimited shelf take-downs or demand registrations.

Sentiment

Score: 6

Explanation: The filing reflects a planned secondary offering by a major investor, which is a neutral to slightly positive event for the investor seeking liquidity. For the company, it's a neutral event as it doesn't raise new capital but could introduce some short-term stock price volatility due to increased supply. The continued significant ownership and board representation by Hellman & Friedman suggest ongoing strategic interest, albeit at a reduced level.

Positives

• The secondary offering provides liquidity for the H&F Selling Stockholders, allowing them to realize value from their investment.
• The company's stock was sold at $51.50 per share, indicating a specific market valuation for the transaction.

Negatives

• A significant shareholder group (Hellman & Friedman) has reduced its stake, which could be perceived as a decrease in conviction or a move towards exiting the investment over time.
• The sale of 1.5 million shares, with an option for an additional 225,000 shares, represents a substantial block of stock entering the market, potentially creating downward pressure on the share price in the short term.

Risks

• Future sales by Hellman & Friedman entities could further dilute their ownership and potentially impact the stock price.
• The exercise of the overallotment option would lead to additional shares being sold by the H&F Selling Stockholders.
• The lock-up agreement expires in 60 days, after which additional shares held by insiders and H&F Selling Stockholders could become available for sale.
• Changes in Hellman & Friedman's ownership percentage could lead to a reduction in their board nomination rights, potentially altering corporate governance influence.

Future Outlook

The Reporting Persons intend to continue reviewing their investment in Claritev Corporation on an ongoing basis and may acquire or dispose of additional shares, engage in hedging, and discuss strategic initiatives with the Issuer's management.

Industry Context

This secondary offering by a major private equity firm (Hellman & Friedman) suggests a partial monetization of their investment in Claritev Corporation. Such moves are common for private equity funds as they mature their investments, seeking to return capital to their limited partners. It indicates a stage in the investment lifecycle where the firm is realizing value, rather than necessarily a negative signal about the company's future, though it does reduce their direct stake and influence.

Comparison to Industry Standards

• The sale of a significant block of shares by a private equity investor like Hellman & Friedman is a standard practice in the private equity lifecycle for portfolio companies that have gone public.
• The lock-up agreement for 60 days is a typical provision in secondary offerings to stabilize the market after the sale, similar to those seen in offerings by companies like Blackstone or KKR for their portfolio exits.
• The tiered board nomination rights based on ownership percentage are also common in investor rights agreements, ensuring proportional representation as an investor's stake changes, comparable to agreements seen with large institutional investors in companies like Vista Equity Partners' portfolio companies.

Corporate Governance

Related Party Transactions

• The sale of shares by H&F Selling Stockholders to underwriters could be considered a related party transaction given H&F's significant ownership and board representation.
• The Amended Investor Rights Agreement outlines ongoing relationships and rights between Hellman & Friedman entities and Claritev Corporation.

Stakeholder Impact

• Shareholders: Increased liquidity for H&F Selling Stockholders. Potential for short-term stock price volatility due to the secondary offering. Long-term shareholders might view the partial exit by a major investor with mixed feelings, depending on their interpretation of H&F's future commitment.
• Company (Claritev Corporation): No direct capital infusion for the company. The transaction primarily facilitates liquidity for existing investors. Continued, albeit reduced, strategic oversight from Hellman & Friedman through board representation.
• Underwriters: Earned an underwriting discount of $2.8325 per share for facilitating the sale.

Next Steps

• The Underwriters may exercise their overallotment option to purchase up to an additional 225,000 shares.
• The 60-day lock-up period for selling stockholders, executive officers, and directors will expire around January 11, 2026.
• Hellman & Friedman entities will continue to review their investment and may acquire or dispose of additional shares.
• Hellman & Friedman entities may engage in discussions with the Issuer's management and other stakeholders regarding operational, financial, and strategic initiatives.

Key Dates

Recommendation

The filing indicates a significant institutional investor, Hellman & Friedman, is partially monetizing its stake in Claritev Corporation through a secondary offering. While this provides liquidity for the selling shareholders and is a natural part of a private equity investment lifecycle, it does not inject new capital into the company. The reduction in Hellman & Friedman's ownership from a higher previous stake (implied by the amendment) to 23.5% (or 22.2% if the overallotment is exercised) suggests a gradual exit strategy. The lock-up period provides short-term stability, but the potential for further sales after its expiration, combined with the reduced, though still substantial, ownership, warrants a 'hold' recommendation. Investors should monitor future sales by Hellman & Friedman and the company's operational performance, as this filing primarily concerns shareholder liquidity rather than fundamental business changes.

Keywords

Claritev Corporation, CLARITEV, Hellman & Friedman, Schedule 13D, Secondary Offering, Stock Sale, Beneficial Ownership, Underwriting Agreement, Investor Rights Agreement, Corporate Governance, Equity Investment, Private Equity Exit